CalciMedica (NASDAQ:CALC) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CalciMedica (NASDAQ:CALC) in a report issued on Tuesday morning,Benzinga reports. They currently have a $16.00 price objective on the stock.

CalciMedica Trading Up 3.2 %

CalciMedica stock opened at $2.27 on Tuesday. The stock has a market cap of $30.60 million, a PE ratio of -2.10 and a beta of 1.18. The stock has a 50-day moving average price of $2.78 and a 200 day moving average price of $3.46. CalciMedica has a 52 week low of $1.86 and a 52 week high of $6.27.

Institutional Trading of CalciMedica

A number of institutional investors have recently modified their holdings of CALC. Atria Investments Inc grew its holdings in shares of CalciMedica by 136.5% during the 3rd quarter. Atria Investments Inc now owns 26,503 shares of the company’s stock worth $117,000 after purchasing an additional 15,296 shares during the period. Geode Capital Management LLC lifted its position in CalciMedica by 51.2% during the 3rd quarter. Geode Capital Management LLC now owns 66,553 shares of the company’s stock worth $295,000 after acquiring an additional 22,525 shares in the last quarter. PVG Asset Management Corp acquired a new position in CalciMedica during the 3rd quarter worth approximately $67,000. Corient Private Wealth LLC acquired a new position in CalciMedica during the 4th quarter worth approximately $135,000. Finally, Renaissance Technologies LLC acquired a new position in CalciMedica during the 4th quarter worth approximately $153,000.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.